Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any cone-rod dystrophy in which the cause of the disease is a mutation in the ADAM9 gene.
Features include: Visual impairment and Cone/cone-rod dystrophy.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 1 | Visual impairment |
Age of onset: childhood.
ADAM9 encodes ADAM metallopeptidase domain 9 (819 aa). Metalloprotease that cleaves and releases a number of molecules with important roles in tumorigenesis and angiogenesis, such as TEK, KDR, EPHB4, CD40, VCAM1 and CDH5.
Cone-rod dystrophy 9 is associated with mutations in the ADAM9 gene on chromosome 8.
The ADAM9 protein participates in Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) pathway.
ADAM9 is classified as a druggable target (Cell Surface, Druggable Genome, Enzyme, External Side Of Plasma Membrane, Neutral Zinc Metallopeptidase, and Protease categories) with score 0.0.
19 pathogenic variants reported in ADAM9 in ClinVar.
Genetic testing for ADAM9 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for cone-rod dystrophy 9 has been reported in the published literature.
No clinical trials have been registered for cone-rod dystrophy 9.
16 publications have been identified in PubMed for cone-rod dystrophy 9. Research spans Epidemiology / Natural History (31%), Basic Science / Preclinical (25%), and Diagnostic / Biomarker (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 5 | 31% |
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 11:14 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about cone-rod dystrophy 9
4 |
25% |
Testing and diagnosis research | 3 | 19% |
Patient case studies | 3 | 19% |
Research summaries | 1 | 6% |
Seela JR (2025). [PMID: 40357345](https://pubmed.ncbi.nlm.nih.gov/40357345/). *J Vitreoretin Dis*. [Case Report / Case Series]
Uner OE (2025). [PMID: 39763288](https://pubmed.ncbi.nlm.nih.gov/39763288/). *Ophthalmic genetics*. [Epidemiology / Natural History]
Demas N (2025). [PMID: 40877827](https://pubmed.ncbi.nlm.nih.gov/40877827/). *BMC medical genomics*. [Diagnostic / Biomarker]
Karuntu JS (2025). [PMID: 39665295](https://pubmed.ncbi.nlm.nih.gov/39665295/). *Acta ophthalmologica*. [Epidemiology / Natural History]
Maximiano-Alves G (2025). [PMID: 39812704](https://pubmed.ncbi.nlm.nih.gov/39812704/). *Neurogenetics*. [Case Report / Case Series]
De Geer K (2025). [PMID: 39643591](https://pubmed.ncbi.nlm.nih.gov/39643591/). *Acta ophthalmologica*. [Diagnostic / Biomarker]
Ferch M (2025). [PMID: 40302276](https://pubmed.ncbi.nlm.nih.gov/40302276/). *The Journal of clinical endocrinology and metabolism*. [Case Report / Case Series]
Drobiova H (2025). [PMID: 40330740](https://pubmed.ncbi.nlm.nih.gov/40330740/). *Journal of diabetes research*. [Basic Science / Preclinical]
Lewis TR (2025). [PMID: 41446234](https://pubmed.ncbi.nlm.nih.gov/41446234/). *bioRxiv : the preprint server for biology*. [Basic Science / Preclinical]
Murgiano L (2025). [PMID: 41325489](https://pubmed.ncbi.nlm.nih.gov/41325489/). *PLoS genetics*. [Basic Science / Preclinical]